Phase 2 Lymphoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are 80 years of age or older at the time of screening, OR people aged 65 to 79 who have been assessed as not suitable for standard chemotherapy combined with immunotherapy
• People who have been diagnosed with a specific type of lymphoma called Diffuse Large B-Cell Lymphoma (DLBCL), confirmed through a tissue biopsy or similar test
• People who have not yet received any treatment for their DLBCL
• People whose lymphoma is classified as Stage II, III, or IV based on a standard staging system used by doctors
• People whose general physical functioning is rated at a certain level (0, 1, or 2 on a standard medical scale), and whose functioning has not declined in the two weeks before joining the trial, unless that decline is directly caused by the lymphoma itself
• People who have at least one measurable area of lymphoma (10mm or larger) that can be seen and tracked on a CT or MRI scan
• People whose organ function (such as kidneys, liver, and blood counts) meets required levels without needing additional medical support, assessed within one week of screening

Who may not be able to join:

• People with severe or poorly controlled health conditions, such as uncontrolled high blood pressure, a history of kidney transplant, or active bleeding conditions
• People with a history of another cancer (past or present) that could affect how the trial is run or how results are interpreted
• People who show signs of an active hepatitis B or hepatitis C infection based on blood tests
• People who have tested positive for HIV or are known to have an HIV infection
• People whose lymphoma has spread to the brain, spinal fluid, or spinal cord
• People whose overall health burden, rated using a specific geriatric health scoring tool (called the CIRS-G), shows a score of 4 in any single category or a total score above 17 (confirm with trial site)
• People with a history of, or currently confirmed to have, a serious brain condition called Progressive Multifocal Leukoencephalopathy
• People with a known active serious infection at the time of screening
• People who have had a stroke or bleeding in the brain within the 6 months before the first dose of the trial drug
• People with a history of a bleeding disorder, such as haemophilia or von Willebrand disease
• People who have had a major surgical procedure within 30 days before the first dose, or who are expected to need major surgery during the trial period
• People who are currently taking or require a blood-thinning medication called warfarin or a similar type of drug (vitamin K antagonists)
• People who have received a live virus vaccine within 28 days before the first dose of the trial drug

Important: Always verify eligibility with the trial site directly before applying.